Debiopharm Research & Manufacturing S.A.

drug modeling
formulation &


What we do

We are a pharmaceutical research, development and production facility, inspected and registered with the main regulatory authorities.

Latest news
January 7, 2019

Debiopharm Group regains the commercial rights to Trelstar® (Triptorelin pamoate) and looks for new partners in North America

Read more
December 13, 2017

Debiopharm et la HES-SO Valais-Wallis célèbrent 20 ans de partenariat public-privé en collaborant au développement d’une nouvelle technologie de marquage…

Read more
See all news

Business model

The Company is a world leader in polylactic-co-glycolic acid (PLGA)-based injectable, sustained-release technology. It has been used for one of our best-selling product Decapeptyl®, a novel injectable controlled-release formulation of triptorelin – a gonadotropin releasing hormone (GnRH) agonist analogue. This mode of administration developed by Debiopharm  Research & Manufacturing relies on the active substance being “encapsulated” in a PLGA polymer to allow gradual dissolution and distribution of the substance in the patient’s body.

The Company has succeeded in producing

  • 1-month,
  • 3-month and
  • 6-month sustained-release (SR) formulations.

It is also focusing on nanoparticular drug delivery systems.


Discover the members who guide and bring long-term vision to the company

Contact us

Got a question or a comment? Get in touch

Contact us